Dostawa leku do badania klinicznego (Tirzepatyd)
Poland · Lublin · how to bid here →
Your path to submission
- Deadline: 16 October at 00:00 — 27 days left.
- The submission point is stated in the notice (link on the right).
- Offer and evidence in: POL.
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- 61% of this buyer's awards went to companies that had already won here before (1,375 awards since 2024, spread over 514 companies). 39% went to new names.n = 1,375 awards since 2024
- The median procedure drew 3 bids (1,246 procedures with a bid count); 22% ended with a single bidder. Sector: median 3 bids.n = 1,246
- 11% of awards went to companies from abroad (1,375 awards with a known winner country). Sector average: 4%.n = 1,375
- < 1% of the bids received came from other countries (405 procedures with a bid mix) — all bidders, not just the winners. Sector: 1%.n = 405
- 50% of the bids received came from small and medium-sized enterprises (405 procedures with a bid mix). Sector: 50%.n = 405
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 17/09/2026.
Foreign bidders
In Poland · Medical equipment & pharma, 5,178 contracts went to foreign companies over the last 3 years (of 274,260 recorded awards) — mostly from Germany, France, Czechia.
Typical field: median 3 (from 1,139 awards).
What the buyer is looking for
The summary in English is being prepared. The official description below is in the original language (DE).
Show original description (DE)
Przedmiotem postępowania jest dostawa leku do badania klinicznego (Tirzepatyd). Zamówienie realizowane jest w ramach projektu finansowanego ze środków budżetu państwa od Agencji Badań Medycznych, numer Projektu 2025/ABM/01/00044 „Niekomercyjne, randomizowane, kontrolowane badanie kliniczne III Fazy typu head to head, oceniające efektywność i bezpieczeństwo zastosowania tirzepatydu i/lub intensywnej insulinoterapii w modelu ciągłego podskórnego wlewu insuliny z wykorzystaniem automatycznego, zaawansowanego hybrydowego systemu zamkniętej pętli u pacjentów z przewlekle niewyrównaną cukrzycą typu 1 i współistniejącą nadwagą (OW) lub chorobą otyłościową oraz towarzyszącymi zaburzeniami neuropsychiatrycznymi.”
Selection criteria — in the procurement documents
The buyer states in the notice that the selection criteria are in the procurement documents (link on the right), not in the EU form. The document analysis below extracts them from there — bid and evidence in Polish.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| MEDTRONIC POLAND Sp. z o.o. | 35 | 2024–2026 |
| Aesculap Chifa Sp. z o.o. · 64-300 PL | 33 | 2024–2026 |
| Bialmed Sp. z o.o. | 31 | 2025–2026 |
| Zarys International Group Sp. z o.o. Sp.k. | 28 | 2024–2026 |
| Balton Sp. z o.o. | 22 | 2025–2026 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.
How to bid
Guide: how to apply on e-Zamówienia (Polen) → Registration, signature, fees — from the operator's bidder manual.